The first accelerated approval for a tumor-agnostic drug was granted by the FDA...
Combining antibiotics with immune response to treat antibiotic resistant bacteria
Researchers from Lehigh University in the US have designed a new possible solution for antibiotic resistant bacteria by combining antibiotics with the exploitation of the body’s immune response.
Upcoming Webinars for Malvern Panalytical
Malvern Panalytical has announced a wide range of upcoming webinars throughout July, including ‘Enter a New Dimension of X-Ray Diffraction Analysis’ and ‘Applications of Light Scattering and Intrinsic Viscosity Detectors with Size Exclusion Chromatography SEC in Characterising Biopharmaceutical and Other Polymers’. To register for any of these webinars, please either make an enquiry using the form on this page or visit www.malvernpanalytical.com/en/learn/events-and-training/webinars.
Malvern Panalytical to Showcase New X-Ray Diffraction Concept at EPDIC16
This year’s European Powder Diffraction Conference (EPDIC16) is the stage for Malvern Panalytical’s new Empyrean platform, an instrument that redefines the concept of multipurpose X-ray diffraction.
Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection
Zepatier is a once-daily oral medicine comprising 50mg of non-structural protein 5A (NS5A) replication complex inhibitor elbasvir and 100mg of NS3/4A protease inhibitor grazoprevir.
Will tumor-agnostic drug development help accelerate precision medicine approaches?
The first accelerated approval for a tumor-agnostic drug was granted by the FDA in May 2017, enabling patients with any locally advanced or metastatic solid tumor expressing particular biomarkers for either microsatellite instability or mismatch repair to receive treatment with Merck & Co’s checkpoint inhibitor, Keytruda.
May’s top news stories
Abivax unveiled new data that may suggest its clinical candidate ABX464 could be a safe, functional cure for human immunodeficiency virus (HIV), as well as a method to treat inflammatory diseases; and Cancer Research UK and Experimental Cancer Medicine Centres (ECMC) Network joint venture (JV) Combinations Alliance started the SeluDex trial, a Phase I clinical study to evaluate selumetinib in combination with dexamethasone for treating leukaemia.
Parsabiv™ (etelcalcetide) for the Treatment of Secondary Hyperparathyroidism (SHPT)
Parsabiv™ (etelcalcetide) is an intravenous injectable calcimimetic agent developed by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) that were previously treated with haemodialysis.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.